Drugs / PM54
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05841563 | Apr 2023 → Dec 2026 expected | neoplasm | PharmaMar | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07644039 | May 2026 → Apr 2029 expected | cancer | PharmaMar | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM54 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07644039 ↗ |
| Route | Intravenous | “Route of administration: Intravenous infusion” NCT05841563 ↗ |